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a b s t r a c t
Triple therapy (TT) with a vitamin K-antagonist (VKA), aspirin, and clopidogrel is currently
recommended as the optimal antithrombotic therapy for patients with an indication for oral
anticoagulation undergoing percutaneous coronary intervention with stent implantation
(PCI-S). While appearing highly effective for preventing the combined incidence of death,
myocardial infarction, repeat revascularization, stent thrombosis, and stroke, TT is associ-
ated with a high incidence of bleeding. In the recent What is the Optimal antiplatElet and
anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST) study,
dual therapy (DT) with warfarin and clopidogrel has been shown to be signiﬁcantly safer
than TT on the occurrence of total bleeding, with no apparent reduction in efﬁcacy, as the
combined incidence of death, myocardial infarction, repeat revascularization,  stent throm-
bosis, and stroke was actually also signiﬁcantly lower in the DT than in the TT arm. Because
of the underpowered size of the WOEST study for a reliable evaluation of the efﬁcacy
outcomes, especially stent thrombosis, and because of the limited superior safety of DT vs
TT for the occurrence of clinically major bleeding, we maintain that the results of the WOEST
study should not precipitously lead to the adoption of DT as the antithrombotic regimen of
choice for patients with an indication for VKA who are submitted to PCI-S.
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Triple therapy (TT) with a vitamin K-antagonist (VKA), aspirin,
and clopidogrel is currently recommended as the optimal
antithrombotic therapy for patients on oral anticoagulation
(OAC) because of atrial ﬁbrillation, a mechanical heart valve, or
other conditions, undergoing percutaneous coronary inter-
vention with stent implantation (PCI-S) [1,2]. While appearing
effective in preventing the combined incidence of death,
myocardial infarction, repeat revascularization, stent throm-
bosis, and stroke, TT is associated with a high incidence of
bleeding [1,2]. Because of the established negative impact of
bleeding on the prognosis of patients undergoing PCI-S [3],
safer antithrombotic regimens in such occurrences have long
been awaited, provided they are not less effective.
The recent What is the Optimal antiplatElet and anticoagulant
therapy in patients with oral anticoagulation and coronary StenTing
(WOEST) study [4] has shown not only that dual therapy of
VKA and clopidogrel (DT) is indeed safer, but is also apparently
more effective, than TT (Table 1). Thus, should now DT be
adopted in clinical practice in patients requiring oral antic-
oagulation and undergoing PCI-S?
To try to answer this question, we will critically review the
design and results of the WOEST study and discuss its
implications [4].
WOEST study design
The prospective, multicenter, randomized design is a major
strength of the WOEST study [4], making it the only
prospective randomized trial carried out so far on OAC
patients submitted to PCI-S, and fulﬁlling most of the formal
requirements for optimal clinical research. Randomization in
fact, gives each participant in the study equal chances of being
assigned to any treatment group, limiting systematic bias;
tends to generate comparable treatment groups; and max-
imizes chances that differences in end points occurring during
the trial are solely due to treatment, thus certainly being the
best way to determine which of any compared treatments is
best.
On the other hand, the open-label design of the WOEST
study [4] weakens the strength of the results, as it may carry
methodological problems. These include: (a) the possible
exclusion from randomization of patients considered to beTable 1 – Safety and efficacy outcomes in the WOEST study [4]
Dual therapy (n = 279) 
Total bleeding 54 (19.4%) 
Death, MI, stroke, TVR, stent thrombosis 31 (11.1%) 
MI: myocardial infarction; TVR: target vessel revascularization.at increased risk of stent thrombosis; (b) over- or under-
reporting the outcome measures by participants; and (c)
physicians' inﬂuence on the reporting of outcome measures.
Indeed, patients enrolled in the WOEST study [4] are younger
than those generally encountered in real-world unselected
populations (mean age about 70 years vs about 73–74 years) [5–
7]; and the incidence of total bleeding is 3-to-4-fold higher than
the average incidences reported in the literature [7,8], and also
much higher than the incidence anticipated at the time of
sample size calculation (44.4% vs 12% in the TT group, and
19.4% vs 5% in the DT group) [4]. While it is unclear whether
such a ﬁnding may have impacted on the results, the
explanation of such high bleeding rate given by the authors
is unsatisfactory [4]. In fact, in another prospective, observa-
tional study enrolling 622 atrial ﬁbrillation patients undergo-
ing PCI-S with drug-eluting stents in all cases, and which
tracked all bleeds – not only major bleeds – and also tended to
prolong the use of clopidogrel because of the systematic use
of drug-eluting stents, the incidences of total bleeding at
12-months were approximately 12% and 7% in the TT and DT
groups (in the latter case comprising warfarin with either
aspirin or clopidogrel), respectively [7], which are about one
third of what was reported in the WOEST study [4].
The main methodological limitation of the WOEST study [4]
is however the small sample size, including only 573 patients
overall. Such sample size provides sufﬁcient power only to
detect differences in the incidence of total bleeding, which was
indeed the primary outcome (a safety outcome) of the study.
No reliably signiﬁcant detection of differences in the second-
ary (efﬁcacy) outcome, including cardiovascular death, myo-
cardial infarction, target vessel revascularization, stent
thrombosis, and stroke, nor – even more – of its individual
components could be done with such numbers, due to their
rarer occurrence.
WOEST study results
Safety
In the WOEST study bleeding episodes were seen in 54 (19.4%)
patients receiving DT and in 126 (44.4%) receiving TT (hazard
ratio [HR] 0.36, 95% CI 0.26–0.50, p < 0.0001). In the DT group, six
(2.2%) patients had multiple bleeding events, compared with
34 (12.0%) in the TT group. Eleven (3.9%) patients receiving DT
required at least one blood transfusion, compared with 27.
Triple therapy (n = 284) Hazard ratio (95% CI) p value
126 (44.4%) 0.36 (0.26–0.50) <0.0001
50 (17.6%) 0.60 (0.38–0.94) 0.025
Table 2 – Differences in the incidence of bleeding in the dual therapy and triple therapy groups of the WOEST study [4].
Not signiﬁcant TIMI major Intra-cranial; decrease of hemoglobin 5 g/dL or hematocrit 15%
GUSTO severe Intra-cranial; leading to hemodynamic compromise
BARC 3c Intra-cranial; intra-ocular with vision impairment
BARC 3b Decrease of hemoglobin 5 g/dL; cardiac tamponade; requiring surgical intervention or inotropic
support
BARC 3a* Decrease of hemoglobin 3–5 g/dL; causing blood transfusion
Signiﬁcant TIMI minimal Decrease of hemoglobin <3 g/dL or hematocrit <9%
TIMI minor Decrease of hemoglobin 3 g/dL or hematocrit 10%; decrease of hemoglobin 4 g/dL or hematocrit
12% with no overt bleeding
GUSTO moderate Causing blood transfusion without hemodynamic compromise
GUSTO mild Not satisfying moderate or severe criteria
BARC 2 Requiring non surgical medical intervention; leading to hospitalization or increased level of care;
prompting evaluation
BARC 1 Not actionable and not requiring unscheduled studies, hospitalization or treatment
TIMI: Thrombolysis In Myocardial Infarction; GUSTO: Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded
coronary arteries; BARC: Bleeding Academic Research Consortium.
* p = 0.054.
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curve 0.39, 95% CI 0.17–0.84, p = 0.011). Although evident – but
also qualitatively expected – the superior safety of DT vs TT in
the trial, when closely inspected, was mostly driven by a
decrease in the incidence of bleeding events of lesser clinical
relevance (TIMI minimal/minor bleeding, GUSTO mild/mod-
erate bleeding, and BARC 1/2/3a bleeding), in the absence of
signiﬁcant differences in the incidence of bleeding of higher
clinical relevance (TIMI major bleeding, GUSTO severe bleed-
ing, and BARC 3b/3c bleeding) (Table 2) [4]. While less clinically
important bleeding events, such as TIMI minimal/minor,
GUSTO mild/moderate, and BARC 1/2/3a bleeds (Table 2) [4],
are known to have some negative prognostic impact (largely
indirect, due to an increase in ischemic events related to the
withdrawal of antithrombotic therapies in response to
bleeding), bleeding events of higher clinical relevance, such
as TIMI major, GUSTO severe, and BARC 3b/3c (Table 2), clearly
impact more and more directly on patients' prognosis [3]. Of
note, the reported lower incidence of GUSTO moderate
(statistically signiﬁcant) and BARC 3a (of borderline statistical
signiﬁcance) bleeding observed in the DT group was also likely
affected by the signiﬁcantly lower rate of blood transfusions
[4], as they represent a classiﬁcation criterion for those types of
bleeding (Table 2). The use of blood transfusions, despite the
existence of recommendations to standardize their use [9],
remains on the one hand extremely subjective, and on the
other hand extremely variable [10], depending on the
complexity of the clinical contexts (comorbidities, hemody-
namic impairment), and possibly also affected by the
knowledge of the therapy given to individual patients due to
the open-label design.
In addition to this, the Kaplan–Meier curves relative to the
incidence of total bleeding appear to diverge immediately and
continue to diverge during the ﬁrst 30 days after randomiza-
tion, but then remain almost parallel up to the end of follow-up
in the WOEST study [4], making the lesser safety of TT vs DT
less attributable to the prolonged exposure to such a regimen,
and, conversely, more dependent on early (peri-PCI-S) vari-
ables. Indeed, the limited use of the radial approach (about
25%), as well as of the continuation of VKA throughout PCI in
about 40% of patients, albeit not different in the two groups [4],may have contributed to the higher incidence of bleeding in
the TT group, receiving a more aggressive antithrombotic
treatment.
Because of these considerations, the still expected differ-
ence in bleeding between the two therapeutic regimens
investigated is less impressive than at ﬁrst sight.
Efﬁcacy
Regarding the combined incidence of cardiovascular death,
myocardial infarction, target vessel revascularization, stent
thrombosis, and stroke, the reported signiﬁcant superiority of
DT over TT appears mostly driven by the reduction of total
mortality (Hazard Ratio [HR] 0.39; 95% CI 0.16–0.93; p = 0.027),
although a numerical, not statistically signiﬁcant, lower
incidence of most of the individual components of the
combined efﬁcacy end point is to be acknowledged [4]. The
lower total mortality in turn appears to be largely driven by the
lower incidence (close to statistical signiﬁcance: HR 0.36; 95%
CI 0.11–1.13; p = 0.069) of non-cardiac mortality, with no
signiﬁcant difference in cardiac mortality (HR 0.43; 95% CI
0.11–1.66; p = 0.207) [4]. In the absence of a plausible patho-
physiological explanation for an effect of antithrombotic
drugs, which should only act by preventing thrombotic
vascular occlusion, on non-cardiac mortality, such an appar-
ent striking result on mortality is possibly due to the play of
chance.
Despite being properly acknowledged by the authors
themselves [4], this limitation is even more relevant when
examining differences in the rare outcome of stent thrombo-
sis, which is the primary rationale for the combination of
aspirin and a P2Y12-receptor inhibitor such as clopidogrel in
other post-PCI-S settings. In WOEST the omission of aspirin in
the DT group was not apparently associated with an increased
rate of stent thrombosis [4]. Since the commonly reported
incidence of stent thrombosis is extremely low (about 1–2%/
year) [11], the absence of a signiﬁcant difference in such an
outcome is not a proof of equal efﬁcacy of the two treatments
because of the high likelihood of a type II error (detecting such
a difference or proving non-inferiority would have required for
both a much larger population).
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 2 5 4 – e 2 5 8 e257Conclusions and practical considerations
The WOEST study essentially conﬁrms, albeit in a prospective,
randomized fashion, previous observations of a better safety
of DT compared to TT in patients on VKA undergoing PCI-S
[7,12,13] and/or receiving combined antithrombotic therapies
[12,13]. The magnitude of beneﬁt on the incidence of total
bleeding with DT compared to TT (about 50–60% in WOEST) is
similar to that observed in large, nationwide, Danish data-
bases [4,12,13]. In such databases, however, the number
needed to harm was nearly the same with TT and DT (12.5
and 15.2, respectively) [12]. Also in accordance with previous
observations [7,8], in the WOEST study [4] the higher safety is
largely attributable to a reduced incidence of minor – rather
than major – bleeding.
Regarding efﬁcacy, the WOEST study [4], largely because of
its size, does not provide deﬁnitive information on the efﬁcacy
of DT vs TT on the incidence of adverse cardiac events,
including death, myocardial infarction, repeat revasculariza-
tion, and especially stent thrombosis. A further caution in
transferring these results to clinical practice is the consider-
ation that, because of the reported inadequate clopidogrel
responsiveness occurring in up to 30% of patients and
associated with an increased risk of adverse cardiac events
[14], such a relevant proportion of patients receiving DT would
actually be exposed to the action of VKA only, an antithrom-
botic regimen which has long been demonstrated to have
insufﬁcient efﬁcacy in preventing adverse cardiac events after
PCI-S [15].
As a whole therefore, the results of WOEST [4] do not
warrant the unrestricted adoption of DT in place of TT as an
antithrombotic treatment for VKA patients undergoing PCI-S.
We acknowledge that further data derived from large,
nationwide, Danish registries have more recently reported
comparable efﬁcacy of DT and TT [16], but such data do not
derive from a prospective randomized trial and are therefore
highly likely to suffer from selection biases. At the moment,
only highly selected patients at very high risk of bleeding and
with a concomitant low risk of stent thrombosis, such as those
undergoing PCI-S for stable coronary artery disease (two-thirds
of patients enrolled in the WOEST study [4]), but also with large
stent diameter and short length stents implanted, and of
young age, might at present be considered candidate for DT. In
general, the WOEST study awaits conﬁrmation from larger
prospective randomized trials. Whether and how DT will
retain a place in the upcoming therapeutic scenario, including
new direct oral anticoagulants (dabigatran, rivaroxaban,
apixaban), and new antiplatelet agents (prasugrel, ticagrelor),
also remains to be investigated.
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